VX-702

• CAT Number: I004768
• CAS Number: 745833-23-2
• Molecular Formula: C19H12F4N4O2
• Molecular Weight: 404.32
• Purity: ≥95%
• Synonyms: 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinecarboxamide
• Target: Autophagy
• Solubility: DMSO: ≥ 42 mg/mL
• Storage: 3 years -20C powder
• IC50: 4-20 nM
• IUPAC Name: 6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)pyridine-3-carboxamide
• InChI: InChI=1S/C19H12F4N4O2/c20-9-4-5-10(14(23)8-9)16-11(18(24)28)6-7-15(26-16)27(19(25)29)17-12(21)2-1-3-13(17)22/h1-8H,(H2,24,28)(H2,25,29)
• InChIKey: FYSRKRZDBHOFAY-UHFFFAOYSA-N
• SMILES: C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F

VX-702（Cat No.:I004768）is a potent and selective inhibitor of p38 MAPK, specifically targeting the p38α and p38β isoforms, which are key mediators of inflammation. By inhibiting p38 MAPK, VX-702 reduces the production of pro-inflammatory cytokines such as TNF-α and IL-1β, effectively suppressing inflammatory responses. It has been investigated for potential use in treating inflammatory diseases, including rheumatoid arthritis and other autoimmune conditions. VX-702 is valuable for research into p38 MAPK’s role in immune regulation, providing insights into therapeutic strategies for inflammatory disorders and conditions associated with excessive immune activation.

Reference

[1]. Kuliopulos A, et al. Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation. Thromb Haemost, 2004, 92(6), 1387-1393.
[2]. Braddock M, IDDB Meeting Report, 2005, March 14-15.
[3]. Gill A, IDDB Meeing Report, 2002, March 06-08.